SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-006569
Filing Date
2020-05-14
Accepted
2020-05-14 11:02:16
Documents
63
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q adap-20200514x10q.htm   iXBRL 10-Q 1520009
2 EX-31.1 adap-20200331xex31d1.htm EX-31.1 11037
3 EX-31.2 adap-20200331xex31d2.htm EX-31.2 11802
4 EX-32.1 adap-20200331xex32d1.htm EX-32.1 6833
5 EX-32.2 adap-20200331xex32d2.htm EX-32.2 6815
  Complete submission text file 0001558370-20-006569.txt   4650490

Data Files

Seq Description Document Type Size
6 EX-101.SCH adap-20200514.xsd EX-101.SCH 35314
7 EX-101.CAL adap-20200514_cal.xml EX-101.CAL 44195
8 EX-101.DEF adap-20200514_def.xml EX-101.DEF 92536
9 EX-101.LAB adap-20200514_lab.xml EX-101.LAB 301451
10 EX-101.PRE adap-20200514_pre.xml EX-101.PRE 225611
30 EXTRACTED XBRL INSTANCE DOCUMENT adap-20200514x10q_htm.xml XML 592997
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37368 | Film No.: 20876158
SIC: 2836 Biological Products, (No Diagnostic Substances)